Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 ...

Preliminary response data for VIR-5818 (HER2-targeted) and VIR-5525 (EGFR-targeted) are expected in 2026 to inform dose ...

(Michael on for Roanna Ruiz), Leerink Partners: "what would constitute a clear signal as a green light to initiate Phase III in 2027?"; President, CEO & Director De Backer: "it's going to really be ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities ...

Beneath the beauty of coral reefs lies a hidden universe of microbes unlike anything scientists expected. Each coral species ...

Virginia has invested in recent years to become a leader in biotechnology. This week, city and state leaders cut the ribbon ...

From the company that restored the dire wolf species comes an ambitious project to bring a long-extinct South African animal ...

Odyssey Therapeutics Inc. raised $304 million in an upsized US initial public offering priced at the top of a marketed range, ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.

The Andrew Hillman Grant for Biotech officially opens its application cycle, offering a strategic opportunity for undergraduate students dedicated to ...